## +HMA WGEO - Rapid Alert Form

Counterfeit or illegal product found in the illegal supply chain

Shaded area to be completed by the secretariat

Reference:	sted by the sec	retariat		
Date:	Time:		Initials:	
Please complete sections		as much		
1. REPORTING PERSON				
Name:		Position:		
Organisation: Pharmaceutical Inspection and Enforcement Department; Spanish Agency for Medicines and Medical Devices (AEMPS)				
Address: Campezo 1, edificio 8, 28022 Madrid (Spain)				
Telephone No: +			Ext:	
e-mail address:				
2. PRODUCT DETAILS				
Product name: - HAVOC	•			
Manufacturer: -RECOMP PERFORMANCE NUTRITION (USA), as declared				
on the label (not verified)				
Importer: -Unknown				
Supplier:				
-Unknown				
Legal status: Banned ☐ Counterfeit ☐ Unlicensed ☒ Stolen ☐				
Dosage form: - Capsule	es			
Strength: as per the labell	ing. <b>2α,3α-ep</b> i	ithio-17α-⊦	methyl-5α-androstan-17β-	
ol, 10 mg				
Batch / lot no: 4500614	s batch numbe	er genuine:	Yes ⊠ No 🗌	
If yes to the above, advise batch destination country: ¿?				
Expiry date: Not provided				
Language of packaging: English				
Date of discovery: Adulteration (undeclared ingredients) detected on:				
- HAVOC: 8 <sup>th</sup> September, 2014				

Details of discovery:				
- HAVOC: Adverse reactions have been notified to Regional Health				
Autorities. After that, a sample of the product was taken by Regional				
Inspection Services from a retailer and submitted to our Agency and analyzed				
by the Official Medicines Control Laboratory (OMCL) of AEMPS and found to				
contain the declared pharmacologically active substance.				
Analysed: YES ⊠ NO □				
If yes, result of analysis: The results of the analysis indicated that this product				
contained the following declared actives substance:				
- HAVOC: 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol				
3. DISTRIBUTION METHOD				
Internet: YES ☐ / NO ☒ (also, not excl	usively through the internet)			
Internet:				
URL:				
Website address:				
Other details:				
Currency of payment:				
Has product reached patients/consumers?	Yes			
4. RISK TO PUBLIC HEALTH				
Adverse reactions: YES ⊠/ NO □				
If yes, please advise details: Adverse real hepatic cholestasis; the presence of methylepitiostanol (prohormone) desoxymethyltestosterone (17α-methors considered to pose a risk to public healt reactions such as hepatic injury and incomplete to the present the presence of the presence	the declared active substance that is metabolized in $\alpha = 10^{1}$ , is th. Also there are risks of adverse			
events. <sup>2</sup> .				
Medical assessment details: hospital admis	ssion caused for hepatic cholestasis			
E NEED FOR BURLICITY				

<sup>&</sup>lt;sup>1</sup> Okano M, Sato M, Ikekita A, Kageyama S. "Analysis of non-ketoic steroids 17alpha-methylepithiostanol and desoxymethyl- testosterone in dietary supplements". Drug Test Analysis.

<sup>2009</sup> Nov;1(11-12):518-25. doi: 10.1002/dta.72. 2http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm174833.htm

Details as per original form
Are you making a public statement? YES ☐ / NO ☒
Are you issuing a press release? YES⊠ / NO □
Are you recalling product? YES ⊠ / NO □
If yes to any of the above, when do you intend to take action?
Action was taken on 09 <sup>th</sup> October, 2014 (recall, note published on AEMPS
website <sup>3</sup> ).
6. DISSEMINATION
Are you content for this Rapid Alert to be shared outside WGEO membership?
YES ⊠ / NO □ (please see below)
If yes, please specify which of the below you are content for this to be shared
with (you may tick more than 1 box)
with (you may tick more than 1 box)  Law Enforcement ☑ Industry Security ☐ Trade Associations ☐
Law Enforcement  Industry Security  Trade Associations

3

## **HAVOC**

